[1]    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57–70.
[2]    Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333(2):328-35.
[3]    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246(4935):1306–1309.
[4]    Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246(4935):1309–1312.
[5]    Kim LA, D’Amore PA. A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis. AJP August 2012; 181(2): 376-379.
[6]    Yang YQ, Tan YY, Wong R, Wenden A, Zhang LK, Rabie ABM. The role of vascular endothelial growth factor in ossification. International Journal of Oral Science 2012; 4(2): 64–68.
[7]    Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. Journal of Internal Medicine 2013; 273(2): 114–127.
[8]    Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A. 1962; 48:1014–1022.
[9]    Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5(8):2145–2154.
[10]    Werb Z, Ashkenas J, MacAuley A, Wiesen JF. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz J Med Biol Res. 1996; 29(9):1087–1097.
[11]    Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression. of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999; 20(5):749–755.
[12]    Murnane MJ, Cai J, Shuja S, McAneny D, Klepeis V, Willett JB. Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer. 2009; 125(12):2893–2902.
[13]    Fonsatti E, Sigalotti L, ArslanP, Altomonte M, Maio M. Emerging Role of Endoglin (CD105) as a Marker of Angiogenesis with Clinical Potential in Human Malignancies. Curr Cancer Drug Targets. 2003; 3(6):427-32.
[14]    Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 2011; 31(6):2283-90.
[15]    Levi B, Wan DC, Glotzbach JP, Hyun J, Januszyk M, Montoro D, et al. CD105 protein depletion enhances human adipose-derived stromal cell osteogenesis through reduction of transforming growth factor β1 (TGF-β1) signaling. J Biol Chem. 2011; 286(45):39497-509.
[16]    Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal câncer. Folia Histochemica et Cytobiologica 2012; 50(1): 12–19.
[17]    Qi JH, Ebrahem Q, Ali M, Cutler A, Bell B, Prayson N, et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal Neovascularization in Mice. PLoS ONE 2013; 8(3): e55667.
[18]    Leifler KS, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J, et al. Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer. J Immunol. 2013; 190(8):4420-30.
[19]    Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 2004; 114(7):898-907.
[20]    Shimizu K, Watanabe K, Yamashita H, Abe M, Yoshimatsu H, Ohta H, et al. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem. Biophys. Res. Commun. 2005; 327(3):700-706.
[21]    Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, et al. Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler. Thromb. Vasc. Biol. 2006; 26(5):1051-1057.
[22]    Kern J, Bauer M, Rychli K, Wojta J, Ritsch A, Gastl G, et al. Alternative splicing of vasohibin-1 generates an inhibitor of endothelial cell proliferation, migration, and capillary tube formation. Arterioscler. Thromb. Vasc. Biol. 2008; 28(3):478-484.
[23]    Sato Y. The vasohibin family: a novel family for angiogenesis regulation. J. Biochem. 2013; 153(1):5–11.
[24]    Goth MI, Hubina E, Raptis S, Nagy GM, Tóth BE. Physiological and pathological angiogenesis in the endocrine system. Microsc Res Tech 2003; 60(1): 98–106.
[25]    Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Moreno-Otero R. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005; 22(1): 23–30.
[26]    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27–31.
[27]    Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature. 2000; 407(6801): 249–257.
[28]    Kuo SW, Ke FC, Chang GD, Lee MT, Hwang JJ. Potential role of follicle-stimulating hormone (FSH) and transforming growth factor (TGFb1) in the regulation of ovarian angiogenesis. J Cell Physiol 2011; 226(6): 1608–1619.
[29]    Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010; 20(8): 863–871.
[30]    Iribarren C, Phelps BH, Darbinian JA, McCluskey ER, Quesenberry CP, Hytopoulos E, et al. Circulating angiopoietins-1 and -2, angiopoietin receptor tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study. BMC Cardiovasc Disord 2011; 11: 31.
[31]    Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8(5): 292–301.
[32]    Ehrmann RL, Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J Natl Cancer Inst 1968; 41(6): 1329–1341.
[33]    Shim WSN, Ho IAW, Wong PEH. Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis. Mol Cancer Res 2007; 5(7):655-665.
[34]    Hu B, Cheng SY. Angiopoietin-2: Development of Inhibitors for Cancer Therapy. Curr Oncol Rep. 2009; 11(2): 111–116.
[35]    Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22:1276-312.
[36]    Madsen CV, Steffensen KD, Waldstrøm M, Andersen RF, Søgaard CH, Brandslund I, et al. Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer. Clinical Ovarian & Other Gynecologic Cancer 2012; 5(1): 10-16.
[37]    Pircher A, Medinger M, DrevS J. Liver cancer: Targeted future options. World J Hepatol. 2011; 3(2): 38–44.
[38]    Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94(6): 715–725.
[39]    Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta–1. Ann Surg Oncol 1998; 5(3): 271–278.
[40]    Goldfarb SB, Hudis C, Dickler MN. Bevacizumab in metastatic breast cancer: when may it be used? Ther Adv Med Oncol 2011; 3(2): 85–93.
[41]    Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, Fujisawa H (1999) A requirement for neuropilin-1 in embryonic vessel formation. Development 126: 4895–4902
[42]    Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735–745.
[43]    Murga M, Fernandez-Capetillo O, Tosato G (2005) Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 105: 1992– 1999.
[44]    Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-Lavigne M, Koch AW, Watts RJ (2007) Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 282: 24049–24056.
[45]    Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155–61.
[46]    Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. Scientific World Journal 2011; 11: 2391–402.
[47]    Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006; 103(33): 12493–8.
[48]    Christoffersson G, Henriksnas J, Johansson L, Rolny C, Ahlström H, Caballero-Corbalan J, et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes 2010; 59(10): 2569–78.
[49]    Xu N, Lei Z, Li XL, Zhang J, Li C, Feng GQ, et al. Clinical Study of Tumor Angiogenesis and Perfusion Imaging Using Multi-slice Spiral Computed Tomography for Breast Cancer. Asian Pacific Journal of Cancer Prevention 2013; 14(1):429-433.
[50]    Brummer O, Athar S, Riethdorf L, Loning T, Herbst H. Matrixmetalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999; 435(6):566 –573.
[51]    Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004; 10(22):7621-7628.
[52]    Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14(7): 1931-1937.
[53]    Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch:a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 2003; 13(7):301-307.
[54]    Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O, et al. CD105 Expression Is a Marker of High Metastatic Risk and Poor Outcome in Breast Carcinomas: Correlations Between Immunohistochemical Analysis and Long-Term Follow-up in a Series of 929 Patients. Am J Clin Pathol 2003; 119(3):374-380.
[55]    Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79(2): 185–188.
[56]    Fox SB, Gatter KC, Harris A. Tumor angiogenesis. J. Pathol. 1996; 179(3): 232–237.
[57]    Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst. 1993; 85(15):1206-19.
[58]    Weidner N. Factor VIII related antigen. J. Natl. Cancer Inst. 1993; 85: 674–675.
[59]    Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast Carcinoma: Vascular Density Determined Using CD105 Antibody Correlates with Tumor Prognosis. Cancer Research 1999; 59(4): 856–861.
[60]    Wang JM, Kumar S, Pye D, Haboubi N, Nakib L. Breast carcinoma; comparative study of tumor vasculature using two endothelial-cell markers. J. Natl. Cancer Inst. 1994; 86(5): 386–388.
[61]    Wang JM, Kumar S, Pye DA, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int. J. Cancer 1993; 54(3): 363–370.
[62]    Pal S, Moulik S, Dutta A, Chatterjee A. Extracellular matrix protein laminin induces matrix metalloproteinase-9 in human breast cancer cell line MCF-7. Cancer Microenviron 2014; 7(1-2):71-78.
[63]    Cardeal LBdS, Boccardo E, Termini L, Rabachini T, Andreoli MA, et al. (2012) HPV16 Oncoproteins Induce MMPs/RECK-TIMP-2 Imbalance in Primary Keratinocytes: Possible Implications in Cervical Carcinogenesis. PLoS ONE 2012; 7(3): e33585.
[64]    Abe M, Sato Y. cDNA microarray analysis of the gene expression profile of VEGF-induced human umbilical vein endothelial cells. Angiogenesis 2001; 4(4):289-298.
[65]    Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H. Distinctive localization and opposed roles of vasohibin‐1 and vasohibin‐2 in the regulation of angiogenesis. Blood 2009; 113(19):4810-4818.
[66]    Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, et al. Vasohibin-2 Expressed in Human Serous Ovarian Adenocarcinoma Accelerates Tumor Growth by Promoting Angiogenesis. Mol Cancer Res. 2012; 10(9):1135-46.